BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van den Heuvel LP, van de Kar NCAJ, Duineveld C, Sarlea A, van der Velden TJAM, Liebrand WTB, van Kraaij S, Schjalm C, Bouwmeester R, Wetzels JFM, Mollnes TE, Volokhina EB. The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cell Mol Immunol 2020;17:653-5. [PMID: 32210393 DOI: 10.1038/s41423-020-0406-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Michels MAHM, van de Kar NCAJ, van Kraaij SAW, Sarlea SA, Gracchi V, Engels FAPT, Dorresteijn EM, van der Deure J, Duineveld C, Wetzels JFM, van den Heuvel LPWJ, Volokhina EB. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Front Immunol 2021;12:715704. [PMID: 34456924 DOI: 10.3389/fimmu.2021.715704] [Reference Citation Analysis]
2 Eliesen GAM, van Drongelen J, van den Broek PHH, Sarlea A, van der Heijden OWH, Langemeijer S, Greupink R, Volokhina EB, Russel FGM. Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. Br J Clin Pharmacol 2021;87:2128-31. [PMID: 32986871 DOI: 10.1111/bcp.14565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Michels MAHM, Wijnsma KL, Kurvers RAJ, Westra D, Schreuder MF, van Wijk JAE, Bouts AHM, Gracchi V, Engels FAPT, Keijzer-Veen MG, Dorresteijn EM, Volokhina EB, van den Heuvel LPWJ, van de Kar NCAJ. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol 2021. [PMID: 34476601 DOI: 10.1007/s00467-021-05221-6] [Reference Citation Analysis]
4 Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C, Ter Heine R, Volokhina EB, Van Den Heuvel LPWJ, Wetzels JFM, van de Kar NCAJ. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient. Front Immunol 2020;11:612706. [PMID: 33519821 DOI: 10.3389/fimmu.2020.612706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]